Speaking of SurgOnc™ is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals of Surgical Oncology.
Once a month, Dr. Greene will interview authors and leading experts in surgical oncology. Speaking of SurgOnc™ episodes will be available on this page and wherever you listen to your favorite podcasts, including Apple Podcasts, Spotify, Stitcher. iHeartRadio and TuneIn.
Episode 1: The 8th Edition of TNM: Implications for the Surgical Oncologist
In the inaugural episode of the Speaking of SurgOnc™ podcast Dr. Rick Greene and Dr. David R. Byrd discuss the 8th edition of the TNM staging system, which through its advances supports the concept of a team approach to cancer staging by clinical oncologists including cancer registrars, pathologists, and radiologists.
Dr. Byrd is co-author with Dr. Greene of the ASO TNM staging editorial, “The 8th Edition of TNM: Implications for the Surgical Oncologist.”
Dr. Byrd is the current Chair of the American Joint Committee on Cancer (AJCC) and his clinical expertise includes surgical oncology, endocrine neoplasms (thyroid, parathyroid, adrenal), breast cancer, melanoma, and Merkel cell carcinoma.
Dr. Byrd is Professor of Surgery and the Section Chief of Surgical Oncology at the University of Washington.
Episode 2: Melanoma Staging: American Joint Committee on Cancer 8th Edition and Beyond
Dr. Greene and Dr. Jeffrey E. Gershenwald discuss the 8th edition of the TNM staging system for melanoma, and its use for communication between physicians and their patients as well as its impact on decision-making and prognostic assessment.
Dr. Gershenwald is co-author with Richard A. Scolyer, MD of the ASO TNM staging editorial, “Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.”
Dr. Gershenwald is a surgical oncologist-investigator in melanoma, with a research focus on integrating clinical, pathological, molecular and immune factors to improve melanoma staging and to develop clinical tools to improve clinical decision-making for patients with melanoma.
Dr. Gershenwald is the Dr. John M. Skibber Professor of Surgery, Department of Surgical Oncology, and Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, and Chair, American Joint Committee on Cancer (AJCC) Melanoma Expert Panel.